| Year |
Citation |
Score |
| 2023 |
Vos JL, Burman B, Jain S, Fitzgerald CWR, Sherman EJ, Dunn LA, Fetten JV, Michel LS, Kriplani A, Ng KK, Eng J, Tchekmedyian V, Haque S, Katabi N, Kuo F, ... ... Ostrovnaya I, et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. Nature Medicine. PMID 37620627 DOI: 10.1038/s41591-023-02518-x |
0.304 |
|
| 2020 |
Mano R, Duzgol C, Ganat M, Goldman DA, Blum KA, Silagy AW, Walasek A, Sanchez A, DiNatale RG, Marcon J, Kashan M, Becerra MF, Benfante N, Coleman JA, Kattan MW, ... ... Ostrovnaya I, et al. Preoperative nomogram predicting 12-year probability of metastatic renal cancer - evaluation in a contemporary cohort. Urologic Oncology. PMID 32900625 DOI: 10.1016/J.Urolonc.2020.07.019 |
0.361 |
|
| 2020 |
Hakimi AA, Attalla K, DiNatale RG, Ostrovnaya I, Flynn J, Blum KA, Ged Y, Hoen D, Kendall SM, Reznik E, Bowman A, Hwee J, Fong CJ, Kuo F, Voss MH, et al. A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nature Communications. 11: 4168. PMID 32820162 DOI: 10.1038/S41467-020-17965-0 |
0.384 |
|
| 2020 |
McPherson V, Reardon B, Bhayankara A, Scott SN, Boyd ME, Garcia-Grossman IR, Regazzi AM, McCoy AS, Kim PH, Al-Ahmadie H, Ostrovnaya I, Roth AJ, Farooki A, Berger MF, Rosenberg JE, et al. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. Cancer. PMID 32767682 DOI: 10.1002/Cncr.33071 |
0.337 |
|
| 2020 |
Teo MY, Mota JM, Whiting KA, Li HA, Funt SA, Lee CH, Solit DB, Al-Ahmadie H, Milowsky MI, Balar AV, Pietzak E, Dalbagni G, Bochner BH, Ostrovnaya I, Bajorin DF, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European Urology. PMID 32753285 DOI: 10.1016/J.Eururo.2020.07.018 |
0.341 |
|
| 2020 |
Kim K, Hu W, Audenet F, Almassi N, Hanrahan AJ, Murray K, Bagrodia A, Wong N, Clinton TN, Dason S, Mohan V, Jebiwott S, Nagar K, Gao J, Penson A, ... ... Ostrovnaya I, et al. Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature Communications. 11: 1975. PMID 32332851 DOI: 10.1038/S41467-020-15885-7 |
0.404 |
|
| 2020 |
Iyer G, Tully CM, Zabor EC, Bochner BH, Dalbagni G, Herr HW, Donat SM, Russo P, Ostrovnaya I, Regazzi AM, Milowsky MI, Rosenberg JE, Bajorin DF. Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. Clinical Genitourinary Cancer. PMID 32273235 DOI: 10.1016/J.Clgc.2020.02.014 |
0.309 |
|
| 2020 |
Ostrovnaya I, Mauguen A, Seshan VE, Begg CB. Testing tumors from different anatomic sites for clonal relatedness using somatic mutation data Biometrics. 77: 283-292. PMID 32135575 DOI: 10.1111/Biom.13256 |
0.362 |
|
| 2020 |
Attalla K, Duzgol C, McLaughlin L, Flynn J, Ostrovnaya I, DiNatale RG, Silagy AW, Coleman J, Lee C, Carlo MI, Voss MH, Russo P, Bilsky M, Hakimi AA, Moss N. The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination. Journal of Clinical Oncology. 38: 742-742. DOI: 10.1200/Jco.2020.38.6_Suppl.742 |
0.302 |
|
| 2020 |
Clinton TN, Whiting K, Silva V, Li Q, Almassi N, Pietzak E, Bagrodia A, Cha EK, Dalbagni G, Iyer G, Bochner BH, Arcila ME, Ostrovnaya I, Gopalan A, Chen Y, et al. Genomic determinants of nested variant urothelial carcinoma. Journal of Clinical Oncology. 38: 538-538. DOI: 10.1200/Jco.2020.38.6_Suppl.538 |
0.357 |
|
| 2020 |
Sarfaty M, Ostrovnaya I, Teo MY, Iyer G, Lee C, Peters V, Durocher J, Regazzi AM, McCoy AS, Hettich G, Al-Ahmadie H, Chaim J, Bajorin DF, Rosenberg JE, Funt SA. A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract. Journal of Clinical Oncology. 38: 514-514. DOI: 10.1200/Jco.2020.38.6_Suppl.514 |
0.343 |
|
| 2020 |
Cha EK, Iyer G, Funt SA, Regazzi AM, Francis J, Heinemann MH, Ostrovnaya I, Dalbagni G, Bajorin DF, Bochner BH, Rosenberg JE. Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer. Journal of Clinical Oncology. 38: 510-510. DOI: 10.1200/Jco.2020.38.6_Suppl.510 |
0.32 |
|
| 2020 |
Burman B, Sherman EJ, Kriplani A, Michel LS, Dunn L, Fetten JV, Warner E, Grewal RK, Sabra M, Tuttle RM, Boucai L, Fish S, Haque S, Ostrovnaya I, Ghossein RA, et al. Radioiodine (RAI) in combination with durvalumab for recurrent/metastatic thyroid cancers. Journal of Clinical Oncology. 38: 6587-6587. DOI: 10.1200/Jco.2020.38.15_Suppl.6587 |
0.314 |
|
| 2020 |
Teo MY, Whiting K, Mota JM, Li H, Regazzi AM, Solit DB, Aggen DH, Lee C, Funt SA, Bajorin DF, Ostrovnaya I, Iyer G, Rosenberg JE. Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC). Journal of Clinical Oncology. 38: 5050-5050. DOI: 10.1200/Jco.2020.38.15_Suppl.5050 |
0.394 |
|
| 2019 |
Sanchez A, Furberg H, Kuo F, Vuong L, Ged Y, Patil S, Ostrovnaya I, Petruzella S, Reising A, Patel P, Mano R, Coleman J, Russo P, Liu CH, Dannenberg AJ, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. The Lancet. Oncology. PMID 31870811 DOI: 10.1016/S1470-2045(19)30797-1 |
0.307 |
|
| 2019 |
Mauguen A, Seshan VE, Ostrovnaya I, Begg CB. An EM algorithm to improve the estimation of the probability of clonal relatedness of pairs of tumors in cancer patients Bmc Bioinformatics. 20: 1-8. PMID 31703552 DOI: 10.1186/S12859-019-3148-Z |
0.303 |
|
| 2019 |
Mano R, Flynn J, Blum KA, Silagy AW, DiNatale RG, Marcon J, Wang A, Sanchez A, Coleman JA, Russo P, Ostrovnaya I, Hakimi AA. The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. Urologic Oncology. PMID 31590969 DOI: 10.1016/J.Urolonc.2019.09.006 |
0.344 |
|
| 2019 |
Silagy AW, Flynn J, Mano R, Blum KA, Marcon J, DiNatale RG, Sanchez A, Carlo MI, Motzer RJ, Coleman JA, Russo P, Ostrovnaya I, Chen YB, Ari Hakimi A. Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urologic Oncology. PMID 31521530 DOI: 10.1016/J.Urolonc.2019.07.011 |
0.37 |
|
| 2019 |
Casuscelli J, Becerra MF, Seier K, Manley BJ, Benfante N, Redzematovic A, Stief CG, Hsieh JJ, Tickoo SK, Reuter VE, Coleman JA, Russo P, Ostrovnaya I, Hakimi AA. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. Clinical Genitourinary Cancer. PMID 31326335 DOI: 10.1016/J.Clgc.2019.06.011 |
0.371 |
|
| 2019 |
Mauguen A, Seshan VE, Begg CB, Ostrovnaya I. Testing clonal relatedness of two tumors from the same patient based on their mutational profiles: update of the Clonality R package. Bioinformatics. 35: 4776-4778. PMID 31198957 DOI: 10.1093/Bioinformatics/Btz486 |
0.352 |
|
| 2019 |
Ahmed FS, Akin O, Shaish H, Luk L, Guo X, Yang H, Zabor E, Ostrovnaya I, Hakimi AA, Zhao B, Schwartz LH. Nonenhancing Component of Clear Cell Renal Cell Carcinoma on Computed Tomography Correlates With Tumor Necrosis and Stage and Serves as a Size-Independent Prognostic Biomarker. Journal of Computer Assisted Tomography. PMID 31162237 DOI: 10.1097/Rct.0000000000000877 |
0.368 |
|
| 2019 |
Tchekmedyian V, Sherman EJ, Dunn L, Tran C, Baxi S, Katabi N, Antonescu CR, Ostrovnaya I, Haque SS, Pfister DG, Ho AL. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801859. PMID 30939095 DOI: 10.1200/Jco.18.01859 |
0.324 |
|
| 2019 |
Hakimi AA, Voss MH, Kuo F, Sanchez A, Liu M, Nixon BG, Vuong L, Ostrovnaya I, Chen YB, Reuter V, Riaz N, Cheng Y, Patel P, Marker M, Reising A, et al. Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear cell Renal Cell Cancer - Data from a Randomized Phase III Trial. Cancer Discovery. PMID 30622105 DOI: 10.1158/2159-8290.Cd-18-0957 |
0.433 |
|
| 2019 |
Hakimi AA, Ged Y, Flynn J, Hoen DR, Di Natale RG, Blum KA, Makarov V, Kuo F, Carlo MI, Lee C, Voss MH, Ostrovnaya I, Chan TA, Motzer RJ. The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB). Journal of Clinical Oncology. 37: 666-666. DOI: 10.1200/Jco.2019.37.7_Suppl.666 |
0.387 |
|
| 2019 |
Funt SA, Jatwani K, Makris M, Regazzi AM, Lee C, Teo MY, McHugh DJ, McCoy AS, Hettich G, Wong P, Abu-Akeel M, Wolchok JD, Merghoub T, Al-Ahmadie H, Ostrovnaya I, et al. A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC). Journal of Clinical Oncology. 37: 4559-4559. DOI: 10.1200/Jco.2019.37.15_Suppl.4559 |
0.325 |
|
| 2019 |
Mano* R, Di Natale R, Drill E, Sankin A, Winer A, Silagy A, Marcon J, Blum K, Reznik E, Coleman J, Ostrovnaya I, Russo P, Hakimi AA. MP16-16 IDENTIFYING CLEAR CELL RCC CLONALITY THROUGH ULTRA-DEEP SEQUENCING OF POOLED REGIONAL TUMOR DNA Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555352.51923.C5 |
0.315 |
|
| 2018 |
Silk MT, Mikkilineni N, Silk TC, Zabor EC, Ostrovnaya I, Hakimi AA, Hsieh JJ, Ziv E, Rekhtman N, Solomon SB, Durack JC. Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics. Analytical Cellular Pathology (Amsterdam). 2018: 2898962. PMID 30652067 DOI: 10.1155/2018/2898962 |
0.322 |
|
| 2018 |
Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill E, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, et al. Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30352907 DOI: 10.1158/1078-0432.Ccr-18-2039 |
0.369 |
|
| 2018 |
Voss MH, Chen D, Reising A, Marker M, Shi J, Xu J, Ostrovnaya I, Seshan V, Redzematovic A, Chen YB, Patel P, Han X, Hsieh JJ, Hakimi AA, Motzer RJ. PTEN Expression, Not Mutation Status for , or , Correlates With Outcome on Everolimus in Patients With Renal Cell Carcinoma Treated on RECORD-3. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30327302 DOI: 10.1158/1078-0432.Ccr-18-1833 |
0.38 |
|
| 2018 |
Modak S, Le Luduec JB, Cheung IY, Goldman DA, Ostrovnaya I, Doubrovina E, Basu E, Kushner BH, Kramer K, Roberts SS, O'Reilly RJ, Cheung NV, Hsu KC. Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. Oncoimmunology. 7: e1461305. PMID 30221057 DOI: 10.1080/2162402X.2018.1461305 |
0.301 |
|
| 2018 |
Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, Herr HW, Huang WC, Taneja SS, Woods M, Ostrovnaya I, Al-Ahmadie H, Arcila ME, Riches JC, Meier A, et al. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017750158. PMID 29742009 DOI: 10.1200/Jco.2017.75.0158 |
0.404 |
|
| 2018 |
Akella SS, Francis JH, Knezevic A, Ostrovnaya I, Gobin YP, Friedman D, Guarini E, Eibeler L, Catalanotti F, Abramson DH. Growth patterns of survivors of retinoblastoma treated with ophthalmic artery chemosurgery. Plos One. 13: e0197052. PMID 29734385 DOI: 10.1371/Journal.Pone.0197052 |
0.314 |
|
| 2018 |
Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, Snyder A, Carlo MI, Solit DB, Berger MF, Funt S, et al. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017757740. PMID 29489427 DOI: 10.1200/Jco.2017.75.7740 |
0.384 |
|
| 2018 |
Reznik E, Luna A, Aksoy BA, Liu EM, La K, Ostrovnaya I, Creighton CJ, Hakimi AA, Sander C. A Landscape of Metabolic Variation across Tumor Types. Cell Systems. PMID 29396322 DOI: 10.1016/J.Cels.2017.12.014 |
0.32 |
|
| 2018 |
Bagrodia A, Kaffenberger S, Winer A, Murray K, Vacchio M, Zheng J, Ostrovnaya I, Bochner BH, Dalbagni G, Cha EK, Coleman JA. Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology. PMID 29344681 DOI: 10.1007/S00345-018-2180-3 |
0.306 |
|
| 2018 |
Mauguen A, Seshan VE, Ostrovnaya I, Begg CB. Estimating the probability of clonal relatedness of pairs of tumors in cancer patients. Biometrics. 74: 321-330. PMID 28482133 DOI: 10.1111/Biom.12710 |
0.392 |
|
| 2018 |
Teo MY, Al-Ahmadie H, Seier K, Ostrovnaya I, Regazzi AM, Dalbagni G, Bochner BH, Funt S, Iyer G, Bajorin DF, Rosenberg JE. Pre-operative chemotherapy (ctx) in plasmacytoid urothelial carcinoma (PUC). Journal of Clinical Oncology. 36: 522-522. DOI: 10.1200/Jco.2018.36.6_Suppl.522 |
0.354 |
|
| 2018 |
Isharwal S, Audenet F, Drill EN, Ostrovnaya I, Pietzak EJ, Al-Ahmadie H, Cha EK, Donahue TF, Teo MY, Funt S, Arcila ME, Berger MF, Rosenberg JE, Bajorin DF, Coleman J, et al. Next generation sequencing of urothelial bladder cancer: Memorial Sloan Kettering Cancer Center experience in 454 patients. Journal of Clinical Oncology. 36: 469-469. DOI: 10.1200/Jco.2018.36.6_Suppl.469 |
0.433 |
|
| 2018 |
Voss MH, Kuo F, Sanchez A, Ostrovnaya I, Cheng Y, Patel P, Marker M, Reising A, Chan TA, Motzer RJ, Hakimi AA. Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis. Journal of Clinical Oncology. 36: 4515-4515. DOI: 10.1200/Jco.2018.36.15_Suppl.4515 |
0.301 |
|
| 2018 |
Isharwal S, Audenet F, Drill E, Ostrovnaya I, Pietzak E, Al-Ahmadie H, Cha E, Donahue T, Teo MY, Funt S, Arcila M, Berger M, Rosenberg J, Bajorin D, Dalbagni G, et al. Mp54-04 Next Generation Sequencing Of Urothelial Bladder Cancer: Memorial Sloan Kettering Cancer Center Experience In 454 Patients The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1695 |
0.312 |
|
| 2018 |
Ghanaat M, Duzgol C, Goldman DA, Blum KA, Kashan M, Becerra MF, Sanchez A, DiNatale R, Nassau D, Casuscelli J, Benfante N, Coleman J, Kattan MW, Russo P, Akin O, ... Ostrovnaya I, et al. Mp36-09 Validation Of The Preoperative Nomogram Predicting 12-Year Probability Of Metastatic Renal Cancer The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1143 |
0.324 |
|
| 2017 |
Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CK, Sakr R, Bernstein JL, Burke KA, King TA, Piscuoglio S, Mauguen A, Orlow I, Weigelt B, Seshan VE, Morrow M, et al. Contralateral Breast Cancers: Independent Cancers or Metastases? International Journal of Cancer. PMID 28921573 DOI: 10.1002/Ijc.31051 |
0.371 |
|
| 2017 |
Isharwal S, Audenet F, Drill E, Pietzak EJ, Iyer G, Ostrovnaya I, Cha E, Donahue T, Arcila M, Jayakumaran G, Berger MF, Rosenberg JE, Bajorin DF, Coleman J, Dalbagni G, et al. Prognostic Value of TERT Alterations and Mutational and Copy Number Alteration Burden in Urothelial Carcinoma. European Urology Focus. PMID 28802642 DOI: 10.1016/J.Euf.2017.07.004 |
0.365 |
|
| 2017 |
Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, ... ... Ostrovnaya I, et al. Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. Jci Insight. 2. PMID 28614790 DOI: 10.1172/Jci.Insight.92688 |
0.377 |
|
| 2017 |
Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, Zehir A, Schultz N, Rosenberg JE, Bajorin DF, Dalbagni G, et al. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. European Urology. PMID 28583311 DOI: 10.1016/J.Eururo.2017.05.032 |
0.331 |
|
| 2017 |
Vakiani E, Shah RH, Berger MF, Makohon-Moore AP, Reiter JG, Ostrovnaya I, Attiyeh MA, Cercek A, Shia J, Iacobuzio-Donahue CA, Solit DB, Weiser MR. Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. Oncotarget. PMID 28476018 DOI: 10.18632/Oncotarget.17200 |
0.39 |
|
| 2017 |
Scott SN, Ostrovnaya I, Lin CM, Bouvier N, Bochner BH, Iyer G, Solit D, Berger MF, Lin O. Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin. Cancer. PMID 28339163 DOI: 10.1002/Cncy.21847 |
0.36 |
|
| 2017 |
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, et al. Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 18: 46. PMID 28249590 DOI: 10.1186/S13059-017-1180-8 |
0.337 |
|
| 2017 |
Teo MY, Bambury R, Zabor EC, Jordan EJ, Al-Ahmadie HA, Boyd M, Bouvier N, Mullane S, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, et al. DNA Damage Response and Repair Gene Alterations Are Associated With Improved Survival In Patients With Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28137924 DOI: 10.1158/1078-0432.Ccr-16-2520 |
0.333 |
|
| 2017 |
Funt S, Mu Z, Cipolla CK, Kania BE, Zheng J, Boyd ME, Charen AS, Callahan MK, Autio KA, Regazzi AM, Moran MM, Ostrovnaya I, Iyer G, Wong P, Lesokhin AM, et al. Evaluation of monocytic myeloid-derived suppressor cell (M-MDSC) frequency in patients with metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology. 35: 356-356. DOI: 10.1200/Jco.2017.35.6_Suppl.356 |
0.311 |
|
| 2017 |
Pietzak EJ, Cha EK, Bagrodia A, Drill EN, Iyer G, Isharwal S, Li Q, Baez P, Berger MF, Zehir A, Ostrovnaya I, Schultz N, Bajorin DF, Rosenberg JE, Dalbagni G, et al. Next generation sequencing of non-muscle invasive bladder cancer to reveal potential biomarkers and rational therapeutic targets. Journal of Clinical Oncology. 35: 302-302. DOI: 10.1200/Jco.2017.35.6_Suppl.302 |
0.384 |
|
| 2017 |
Teo M, Hao X, Desai N, Ostrovnaya I, Arora A, Funt S, Gopalan A, Chen Y, Fine S, Bochner BH, Dalbagni G, Taylor BS, Berger MF, Solit DB, Tickoo S, et al. Small cell carcinoma of the bladder (SCCB): Clinical, histopathologic, and genomic predictors of clinical outcomes. Journal of Clinical Oncology. 35: 294-294. DOI: 10.1200/Jco.2017.35.6_Suppl.294 |
0.358 |
|
| 2017 |
Teo M, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, Solit DB, Funt S, Wolchok JD, Iyer G, Charen AS, et al. DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology. 35: 4509-4509. DOI: 10.1200/Jco.2017.35.15_Suppl.4509 |
0.356 |
|
| 2016 |
Padovan-Merhar OM, Raman P, Ostrovnaya I, Kalletla K, Rubnitz KR, Sanford EM, Ali SM, Miller VA, Mossé YP, Granger MP, Weiss B, Maris JM, Modak S. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. Plos Genetics. 12: e1006501. PMID 27997549 DOI: 10.1371/Journal.Pgen.1006501 |
0.383 |
|
| 2016 |
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 17: 231. PMID 27855702 DOI: 10.1186/S13059-016-1092-Z |
0.343 |
|
| 2016 |
Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, et al. Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27646943 DOI: 10.1200/Jco.2016.68.7798 |
0.365 |
|
| 2016 |
O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF. Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clinical Genitourinary Cancer. PMID 27150640 DOI: 10.1016/J.Clgc.2016.03.006 |
0.4 |
|
| 2016 |
Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, Jordan EJ, Gao SP, Ramirez R, Cha EK, Desai NB, Zabor EC, Ostrovnaya I, Gopalan A, Chen YB, et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature Genetics. PMID 26901067 DOI: 10.1038/Ng.3503 |
0.399 |
|
| 2016 |
Winer AG, Senbabaoglu Y, Gejman R, Ostrovnaya I, Kaffenberger SD, Voss MH, Coleman JA, Russo P, Hsieh J, Sander C, Hakimi AA. The immune landscape of renal cell carcinoma and its association with intratumoral clonality. Journal of Clinical Oncology. 34: 605-605. DOI: 10.1200/Jco.2016.34.2_Suppl.605 |
0.372 |
|
| 2016 |
Bagrodia A, Kaffenberger SD, Lee B, Lee W, Cha EK, Sfakianos J, Gao SP, Zabor EC, Ostrovnaya I, Eng J, Berger MF, Bajorin DF, Schultz N, Sheinfeld J, Bosl GJ, et al. Actionable targets in patients with cisplatin-resistant advanced germ cell tumors. Journal of Clinical Oncology. 34: 473-473. DOI: 10.1200/Jco.2016.34.2_Suppl.473 |
0.409 |
|
| 2016 |
Balar AV, Iyer G, Milowsky MI, Huang WC, Woods M, Donat SM, Herr HW, Dalbagni G, Bochner BH, Ostrovnaya I, Al-Ahmadie H, Rose TL, Riches JC, Kania BE, Regazzi AM, et al. Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC). Journal of Clinical Oncology. 34: 436-436. DOI: 10.1200/Jco.2016.34.2_Suppl.436 |
0.338 |
|
| 2016 |
Iyer G, Balar AV, Milowsky MI, Huang WC, Woods M, Donat SM, Herr HW, Dalbagni G, Bochner BH, Ostrovnaya I, Al-Ahmadie H, Rose TL, Riches JC, Kania BE, Boyd ME, et al. Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC). Journal of Clinical Oncology. 34: 5011-5011. DOI: 10.1200/Jco.2016.34.15_Suppl.5011 |
0.325 |
|
| 2016 |
Dobrenkov K, Ostrovnaya I, Cheung IY, Feng Y, Cheung NV. GD2/GD3 expression: Companion diagnostic for ganglioside-targeted immunotherapy against pediatric solid tumors. Journal of Clinical Oncology. 34: 10567-10567. DOI: 10.1200/Jco.2016.34.15_Suppl.10567 |
0.35 |
|
| 2016 |
Roberts SS, Ogando Y, Ostrovnaya I, Fattahi F, Cheung I, Cheung NV, Studer L, Tomishima M. Abstract A08: Using directed differentiation of human pluripotent stem cells and gene expression profiling to characterize the cell of origin of neuroblastoma Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-A08 |
0.318 |
|
| 2016 |
Bagrodia A, Lee B, Lee W, Cha E, Sfakianos J, Gao P, Zabor E, Ostrovnaya I, Kaffenberger S, Eng J, Berger M, Bajorin D, Schultz N, Sheinfeld J, Bosl G, et al. Mp81-15 Genetic Basis For Cisplatin Resistance In Patients With Advanced Germ Cell Tumors (Gct) The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2068 |
0.338 |
|
| 2015 |
Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NV. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. PMID 26623730 DOI: 10.18632/Oncotarget.6393 |
0.347 |
|
| 2015 |
Tully CM, Apolo AB, Zabor EC, Regazzi AM, Ostrovnaya I, Furberg HF, Rosenberg JE, Bajorin DF. The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. Cancer. PMID 26618338 DOI: 10.1002/Cncr.29801 |
0.377 |
|
| 2015 |
Ostrovnaya I, Seshan VE, Begg CB. Using Somatic Mutation Data To Test Tumors For Clonal Relatedness. The Annals of Applied Statistics. 9: 1533-1548. PMID 26594266 DOI: 10.1214/15-Aoas836 |
0.37 |
|
| 2015 |
Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R, Sankin AI, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, et al. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer. PMID 26505625 DOI: 10.1002/cncr.29765 |
0.392 |
|
| 2015 |
Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, Ren Q, Bagrodia A, Kim PH, Hakimi AA, Ostrovnaya I, Ramirez R, Hanrahan AJ, Desai NB, Sun A, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. European Urology. PMID 26278805 DOI: 10.1016/J.Eururo.2015.07.039 |
0.351 |
|
| 2015 |
Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Kramer K, Modak S, Yataghene K, Cheung NK. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study. Oncoimmunology. 4: e1016704. PMID 26140243 DOI: 10.1080/2162402X.2015.1016704 |
0.353 |
|
| 2015 |
Bambury RM, Benjamin DJ, Chaim JL, Zabor EC, Sullivan J, Garcia-Grossman IR, Regazzi AM, Ostrovnaya I, Apollo A, Xiao H, Voss MH, Iyer G, Bajorin DF, Rosenberg JE. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. The Oncologist. 20: 508-15. PMID 25845990 DOI: 10.1634/Theoncologist.2014-0354 |
0.356 |
|
| 2015 |
Kushner BH, Roberts SS, Friedman DN, Kuk D, Ostrovnaya I, Modak S, Kramer K, Basu EM, Cheung NK. Osteochondroma in long-term survivors of high-risk neuroblastoma. Cancer. 121: 2090-6. PMID 25728463 DOI: 10.1002/Cncr.29316 |
0.33 |
|
| 2015 |
Kim PH, Cha EK, Sfakianos JP, Iyer G, Zabor EC, Scott SN, Ostrovnaya I, Ramirez R, Sun A, Shah R, Yee AM, Reuter VE, Bajorin DF, Rosenberg JE, Schultz N, et al. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. European Urology. 67: 198-201. PMID 25092538 DOI: 10.1016/J.Eururo.2014.06.050 |
0.409 |
|
| 2015 |
Gonzalez CM, Jordan E, Zabor EC, Kania BE, Regazzi AM, Ostrovnaya I, Iyer G, Bajorin DF, Bambury RM, Rosenberg JE. Split-dose cisplatin as an alternative to every-3-week dosing when using cisplatin/gemcitabine to treat advanced urothelial cancer. Journal of Clinical Oncology. 33: 373-373. DOI: 10.1200/Jco.2015.33.7_Suppl.373 |
0.36 |
|
| 2015 |
Abida W, Milowsky MI, Ostrovnaya I, Gerst SR, Rosenberg JE, Regazzi AM, McCoy AS, Boyd ME, Bajorin DF. Phase I trial of gemcitabine and split-dose cisplatin plus everolimus (RAD001) in patients with advanced urothelial cancer. Journal of Clinical Oncology. 33: 322-322. DOI: 10.1200/Jco.2015.33.7_Suppl.322 |
0.326 |
|
| 2015 |
Bambury RM, Jordan E, Zabor EC, Bouvier N, Al-Ahmadie H, Boyd ME, Mullane SA, Cha EK, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Bajorin DF, Bellmunt J, et al. Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma. Journal of Clinical Oncology. 33: 4532-4532. DOI: 10.1200/Jco.2015.33.15_Suppl.4532 |
0.357 |
|
| 2015 |
Feldman DR, Bagrodia A, Lee B, Lee W, Al-Ahmadie H, Cha EK, Sfakianos J, Iyer G, Zabor EC, Ostrovnaya I, Eng J, Arcila ME, Chaganti RSK, Schultz N, Reuter VE, et al. Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT) Journal of Clinical Oncology. 33: 4510-4510. DOI: 10.1200/Jco.2015.33.15_Suppl.4510 |
0.384 |
|
| 2015 |
Scott SN, Sfakianos JP, Cha EK, Iyer G, Zabor EC, Kim PH, Hakimi AA, Ostrovnaya I, Ramirez R, Hanrahan AJ, Desai N, Ren Q, Sun A, Rosenberg JE, Dalbagni G, et al. Abstract LB-174: Examining the genomic differences between upper and lower tract urothelial carcinomas Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-174 |
0.425 |
|
| 2015 |
Bagrodia A, Cha E, Sfakianos J, Iyer G, Lee B, Scott S, Zabor E, Shah R, Ren Q, Kim P, Hakimi A, Ostrovnaya I, Rosenberg J, Dalbagni G, Bajorin D, et al. MP7-13 GENETIC SIGNATURES ARE ASSOCIATED WITH ADVERSE PATHOLOGIC AND CLINICAL OUTCOMES IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA (UTUC) Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.220 |
0.333 |
|
| 2015 |
Kaffenberger S, Ostrovnaya I, Winer A, Reuter V, Coleman J, Russo P, Hsieh J, Hakimi A. MP44-07 A CRITICAL ANALYSIS AND VALIDATION OF THE RENAL CELL CARCINOMA BIOMARKER LITERATURE USING THE CANCER GENOME ATLAS (TCGA) Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1549 |
0.358 |
|
| 2014 |
Cheung NK, Modak S, Ostrovnaya I, Roberts SS, Basu EM, Kramer K, Kushner BH. When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 4173-4. PMID 25403224 DOI: 10.1200/Jco.2014.58.1678 |
0.325 |
|
| 2014 |
Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Medicine. 3: 1485-92. PMID 25124064 DOI: 10.1002/Cam4.293 |
0.366 |
|
| 2014 |
Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discovery. 4: 1140-53. PMID 25096233 DOI: 10.1158/2159-8290.Cd-14-0623 |
0.415 |
|
| 2014 |
Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Inagaki A, Schultz N, Hanrahan AJ, Scott SN, Brannon AR, McDermott GC, Pirun M, Ostrovnaya I, Kim P, Socci ND, Viale A, et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discovery. 4: 1014-21. PMID 24934408 DOI: 10.1158/2159-8290.Cd-14-0380 |
0.42 |
|
| 2014 |
Cheung NKV, Cheung IY, Kramer K, Modak S, Kuk D, Pandit-Taskar N, Chamberlain E, Ostrovnaya I, Kushner BH. Key role for myeloid cells: Phase II results of anti-GD2 antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma International Journal of Cancer. 135: 2199-2205. PMID 24644014 DOI: 10.1002/Ijc.28851 |
0.306 |
|
| 2014 |
Taylor JM, Yaneva M, Velasco K, Philip J, Erdjument-Bromage H, Ostrovnaya I, Lilja HG, Bochner BH, Tempst P. Aminopeptidase activities as prospective urinary biomarkers for bladder cancer. Proteomics. Clinical Applications. 8: 317-26. PMID 24591208 DOI: 10.1002/Prca.201300118 |
0.329 |
|
| 2014 |
Hakimi AA, Mano R, Ciriello G, Gonen M, Mikkilineni N, Sfakianos JP, Kim PH, Motzer RJ, Russo P, Reuter VE, Hsieh JJ, Ostrovnaya I. Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma. The Journal of Urology. 192: 24-9. PMID 24518768 DOI: 10.1016/J.Juro.2014.01.088 |
0.404 |
|
| 2014 |
Karlo CA, Di Paolo PL, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, Hricak H, Motzer R, Hsieh JJ, Akin O. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology. 270: 464-71. PMID 24029645 DOI: 10.1148/Radiol.13130663 |
0.308 |
|
| 2014 |
Tully CM, Bochner BH, Dalbagni G, Zabor EC, Herr HW, Donat SM, Ostrovnaya I, Regazzi AM, Kim PH, Sfakianos JP, Rosenberg JE, Bajorin DF. Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND. Journal of Clinical Oncology. 32: 355-355. DOI: 10.1200/Jco.2014.32.4_Suppl.355 |
0.344 |
|
| 2014 |
Kopp RP, Stratton KL, Garcia-Grossman IR, Zabor EC, Ostrovnaya I, Thomas T, Gerber G, Alanee SR, Schrader KA, O'Donnell PH, Bajorin DF, Joseph V, Offit K. Pilot investigation of variants in DNA repair pathways and association with response to platinum-based chemotherapy in bladder cancer. Journal of Clinical Oncology. 32: 343-343. DOI: 10.1200/Jco.2014.32.4_Suppl.343 |
0.369 |
|
| 2014 |
O'Donnell PH, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Stratton KL, Manschreck C, Smith ND, Steinberg GD, Joseph V, Offit K, Stadler WM, Bajorin DF. Clinical evaluation of cisplatin sensitivity germ line polymorphisms in neoadjuvant chemotherapy (NAC) for urothelial cancer (UC). Journal of Clinical Oncology. 32: 342-342. DOI: 10.1200/Jco.2014.32.4_Suppl.342 |
0.342 |
|
| 2014 |
Benjamin DJ, Bambury RM, Chaim J, Zabor EC, Ostrovnaya I, Garcia-Grossman IR, Iyer G, Bajorin DF, Rosenberg JE. Efficacy of single-agent pemetrexed in platinum refractory metastatic urothelial cancer (mUC). Journal of Clinical Oncology. 32: 322-322. DOI: 10.1200/Jco.2014.32.4_Suppl.322 |
0.379 |
|
| 2014 |
Tully CM, Apolo AB, Zabor EC, Regazzi AM, Ostrovnaya I, Rosenberg JE, Bajorin DF. The high incidence of vascular thromboembolic events (VTE) in advanced urothelial cancer (UC) patients (pts) treated with carboplatin (Cb): Analysis of treatment with gemcitabine (G)/cb (GCb), gcb/bevacizumab (GCbBev), or gemcitabine/cisplatin (GCis). Journal of Clinical Oncology. 32: 316-316. DOI: 10.1200/Jco.2014.32.4_Suppl.316 |
0.319 |
|
| 2014 |
Rosenberg JE, Van Allen EM, Mouw KW, Kim PH, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Iyer G, Signoretti S, Reuter VE, Getz G, Kantoff PW, Bochner BH, Choueiri TK, et al. Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Journal of Clinical Oncology. 32: 4510-4510. DOI: 10.1200/Jco.2014.32.15_Suppl.4510 |
0.426 |
|
| 2014 |
Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. Erratum: Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemothery (Journal of the National Cancer Institute (2013) 105:7 (499-503)) Journal of the National Cancer Institute. 106. DOI: 10.1093/Jnci/Dju096 |
0.366 |
|
| 2014 |
Kopp R, Stratton K, Garcia-Grossman I, Zabor E, Ostrovnaya I, Thomas T, Gerber G, Alanee S, Schrader K, Corines M, O'Donnell P, Bajorin D, Joseph V, Offit K. Mp61-05 Pilot Investigation Of Variants In Dna Repair Pathways And Association With Response To Platinum-Based Chemotherapy In Bladder Cancer. The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1882 |
0.337 |
|
| 2014 |
Hakimi AA, Ostrovnaya I, Jacobsen A, Coleman J, Russo P, Mano R, Sankin A, Motzer RJ, Purdue M, Pomerantz M, Freedman M, Choueiri T, Hsieh JJ, Klein RJ. Mp36-02 Validation And Genomic Interrogation Of The Met Variant Rs11762213 As A Predictor Of Adverse Outcomes In Clear Cell Renal Cell Carcinoma The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1066 |
0.326 |
|
| 2013 |
Shah S, Stratton KL, Garcia-Grossman IR, Zabor E, Ostrovnaya I, Joseph V, Pendse D, Bajorin DF, Offit K. Exome sequencing of extreme phenotypes to identify variants predictive of response to chemotherapy in bladder cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 300. PMID 28137136 DOI: 10.1200/Jco.2013.31.6_Suppl.300 |
0.387 |
|
| 2013 |
Ostrovnaya I, Voss MH, Motzer RJ, Russo P, Reuter VE, Hsieh J. Association of mutations in chromatin modifiers with poor survival in clear cell renal cell carcinoma: Analysis of the Cancer Genome Atlas Project. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 360. PMID 28136797 DOI: 10.1200/Jco.2013.31.6_Suppl.360 |
0.422 |
|
| 2013 |
Alanee S, Cao H, Ostrovnaya I, Garcia-Grossman IR, Ganshert C, Smith ND, Steinberg GD, Offit K, Stadler WM, Bajorin DF. Prediction of pathologic complete response to neoadjuvant chemotherapy in urothelial cancer by genetic determinants of platinum sensitivity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 290. PMID 28136779 DOI: 10.1200/Jco.2013.31.6_Suppl.290 |
0.395 |
|
| 2013 |
Iyer G, Riester M, Werner L, Schultz N, Stack EC, Park R, Loda M, Ostrovnaya I, Kantoff PW, Bajorin DF, Solit DB, Michor F, Bellmunt J, Rosenberg JE. Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 279. PMID 28136741 DOI: 10.1200/Jco.2013.31.6_Suppl.279 |
0.316 |
|
| 2013 |
Cobrinik D, Ostrovnaya I, Hassimi M, Tickoo SK, Cheung IY, Cheung NK. Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases. Genes, Chromosomes & Cancer. 52: 1150-66. PMID 24123354 DOI: 10.1002/Gcc.22110 |
0.314 |
|
| 2013 |
Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, Kim PH, Lin O, Weinhold N, Sander C, Zabor EC, Janakiraman M, Garcia-Grossman IR, Heguy A, Viale A, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3133-40. PMID 23897969 DOI: 10.1200/Jco.2012.46.5740 |
0.388 |
|
| 2013 |
Gallagher DJ, Vijai J, Hamilton RJ, Ostrovnaya I, Iyer G, Garcia-Grossman IR, Kim PH, Przybylo JA, Alanee S, Riches JC, Regazzi AM, Milowsky MI, Offit K, Bajorin DF. Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2414-21. PMID 23897706 DOI: 10.1093/Annonc/Mdt225 |
0.342 |
|
| 2013 |
Shah S, Kim Y, Ostrovnaya I, Murali R, Schrader KA, Lach FP, Sarrel K, Rau-Murthy R, Hansen N, Zhang L, Kirchhoff T, Stadler Z, Robson M, Vijai J, Offit K, et al. Assessment of SLX4 Mutations in Hereditary Breast Cancers. Plos One. 8: e66961. PMID 23840564 DOI: 10.1371/Journal.Pone.0066961 |
0.309 |
|
| 2013 |
Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, Liu H, Takeda S, Voss MH, Tickoo SK, Reuter VE, Russo P, Cheng EH, Sander C, Motzer RJ, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3259-67. PMID 23620406 DOI: 10.1158/1078-0432.Ccr-12-3886 |
0.417 |
|
| 2013 |
Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, Gellert LL, Kaplan R, Garcia-Grossman IR, Pendse D, Balar AV, Flaherty AM, Trout A, Solit DB, Bajorin DF. Phase II study of everolimus in metastatic urothelial cancer. Bju International. 112: 462-70. PMID 23551593 DOI: 10.1111/J.1464-410X.2012.11720.X |
0.414 |
|
| 2013 |
Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. Journal of the National Cancer Institute. 105: 499-503. PMID 23411591 DOI: 10.1093/Jnci/Djt015 |
0.324 |
|
| 2013 |
Balar AV, Apolo AB, Ostrovnaya I, Mironov S, Iasonos A, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Milowsky MI, Bajorin DF. Phase ii study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer Journal of Clinical Oncology. 31: 724-730. PMID 23341513 DOI: 10.1200/Jco.2012.42.5215 |
0.365 |
|
| 2013 |
Kobos R, Nagai M, Tsuda M, Merl MY, Saito T, Laé M, Mo Q, Olshen A, Lianoglou S, Leslie C, Ostrovnaya I, Antczak C, Djaballah H, Ladanyi M. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein. The Journal of Pathology. 229: 743-54. PMID 23288701 DOI: 10.1002/Path.4158 |
0.304 |
|
| 2013 |
Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen Y, Gonen M, Liu H, Takeda S, Tickoo SK, Voss MH, Cheng EH, Reuter VE, Motzer RJ, Russo P, Hsieh JJ. 1068 ADVERSE OUTCOMES IN CLEAR CELL RENAL CELL CARCINOMA WITH MUTATIONS OF EPIGENETIC REGULATORS BAP1 AND SETD2 Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.657 |
0.322 |
|
| 2013 |
Alanee S, Shah S, Stratton K, Garcia-Grossman I, Zabor E, Ostrovnaya I, Joseph V, Pendse D, Bajorin D, Offit K. 915 Exome Sequencing Of Extreme Phenotypes To Identify Variants Predictive Of Response To Chemotherapy In Bladder Cancer The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.492 |
0.373 |
|
| 2012 |
Alanee S, Gallagher DJ, Vijai J, Hamilton RJ, Ostrovnaya I, Garcia-Grossman IR, Riches JC, Regazzi AM, Przybylo JA, Gaudet M, Milowsky MI, Herr HW, Offit K, Bajorin DF. Association of single-nucleotide polymorphisms in BCL2L1 and TACC3 with response to bacillus Calmette-Guérin intravesical therapy in non-muscle-invasive bladder cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 260. PMID 27968264 DOI: 10.1200/Jco.2012.30.5_Suppl.260 |
0.317 |
|
| 2012 |
Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science (New York, N.Y.). 338: 221. PMID 22923433 DOI: 10.1126/Science.1226344 |
0.352 |
|
| 2012 |
Cheung NKV, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte- macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission Journal of Clinical Oncology. 30: 3264-3270. PMID 22869886 DOI: 10.1200/Jco.2011.41.3807 |
0.324 |
|
| 2012 |
Ostrovnaya I. Testing clonality of three and more tumors using their loss of heterozygosity profiles. Statistical Applications in Genetics and Molecular Biology. 11: 1-30. PMID 22850066 DOI: 10.1515/1544-6115.1757 |
0.355 |
|
| 2012 |
Andrade VP, Ostrovnaya I, Seshan VE, Morrogh M, Giri D, Olvera N, Brot MD, Morrow M, Begg CB, King TA. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions Breast Cancer Research. 14: 1-14. PMID 22776144 DOI: 10.1186/Bcr3222 |
0.312 |
|
| 2012 |
Ostrovnaya I, Nicolae DL. Estimating the proportion of true null hypotheses under dependence Statistica Sinica. 22: 1689-1716. DOI: 10.5705/Ss.2010.255 |
0.463 |
|
| 2012 |
Balar AV, Iyer G, Al-Ahmadie H, Janakiraman M, Ostrovnaya I, Regazzi AM, Garcia-Grossman IR, Pendse D, Bochner B, Bajorin DF, Milowsky MI, Solit DB. Alterations in the PI3K/Akt signaling pathway and association with outcome in invasive high-grade urothelial cancer (UC). Journal of Clinical Oncology. 30: 277-277. DOI: 10.1200/Jco.2012.30.5_Suppl.277 |
0.389 |
|
| 2012 |
Alanee S, Hamilton RJ, Joseph V, Ostrovnaya I, Garcia-Grossman IR, Gallagher DJ, Pendse D, Regazzi AM, Przybylo JA, Gaudet M, Milowsky MI, Herr HW, Offit K, Bajorin DF. Single nucleotide polymorphisms as markers of bacillus Calmette-Guérin intravesical therapy response in non-muscle invasive bladder cancer. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15022 |
0.322 |
|
| 2012 |
Apolo AB, Philips G, Ostrovnaya I, Rosenberg JE, Milowsky MI, Small EJ, Bajorin DF, Halabi S. External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. Journal of Clinical Oncology. 30: 4592-4592. DOI: 10.1200/Jco.2012.30.15_Suppl.4592 |
0.36 |
|
| 2012 |
Balar AV, Iyer G, Apolo AB, Regazzi AM, Garcia-Grossman IR, Pendse D, Ostrovnaya I, Chou JF, Bochner B, Dalbagni G, Herr HW, Milowsky MI, Bajorin DF. Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC). Journal of Clinical Oncology. 30: 4581-4581. DOI: 10.1200/Jco.2012.30.15_Suppl.4581 |
0.325 |
|
| 2012 |
Alanee S, Gallagher D, Vijai J, Hamilton R, Ostrovnaya I, Garcia-Grossman I, Regazzie A, Littman J, Jennifer P, Manschreck C, Gaudet M, Milowsky M, Herr H, Offit K, Bajorin D. 566 IDENTIFICATION OF GENETIC MARKERS ASSOCIATED WITH RESPONSE TO BACILLUS CALMETTE-GUÉRIN INTRAVESICAL THERAPY IN NON-MUSCLE-INVASIVE BLADDER CANCER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.641 |
0.325 |
|
| 2011 |
Gallagher DJ, Joseph V, Hamilton RJ, Ostrovnaya I, Garcia-Grossman IR, Riches JC, Regazzi AM, Przybylo JA, Gaudet M, Milowsky MI, Offit K, Bajorin DF. Association of germ-line variation with platinum-based chemotherapy response in patients (pts) with urothelial carcinoma (UC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4511. PMID 28023452 DOI: 10.1200/Jco.2011.29.15_Suppl.4511 |
0.378 |
|
| 2011 |
Gallagher D, Joseph V, Garcia-Grossman IR, Przybylo JA, Riches JC, Ostrovnaya I, Hamilton R, Milowsky MI, Offit K, Bajorin DF. Germline single-nucleotide polymorphisms (SNPs) associated with response of urothelial carcinoma (UC) to platinum-based therapy: The role of the host. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 236. PMID 27968658 DOI: 10.1200/Jco.2011.29.7_Suppl.236 |
0.355 |
|
| 2011 |
Gallagher DJ, Al-Ahmadie H, Ostrovnaya I, Gerst SR, Regazzi A, Garcia-Grossman I, Riches J, Gounder SK, Flaherty AM, Trout A, Milowsky MI, Bajorin DF. Sunitinib in urothelial cancer: Clinical, pharmacokinetic, and immunohistochemical study of predictors of response European Urology. 60: 344-349. PMID 21645967 DOI: 10.1016/J.Eururo.2011.05.034 |
0.349 |
|
| 2011 |
Ostrovnaya I, Seshan VE, Olshen AB, Begg CB. Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles. Bioinformatics. 27: 1698-1699. PMID 21546399 DOI: 10.1093/Bioinformatics/Btr267 |
0.352 |
|
| 2011 |
Balar AV, Milowsky MI, Apolo AB, Ostrovnaya I, Iasonos A, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Bajorin DF. Phase II trial of gemcitabine, carboplatin, and bevacizumab in chemotherapy-naive patients (Pts) with advanced/metastatic urothelial carcinoma (UC). Journal of Clinical Oncology. 29: 248-248. DOI: 10.1200/Jco.2011.29.7_Suppl.248 |
0.342 |
|
| 2011 |
Milowsky MI, Regazzi AM, Garcia-Grossman IR, Trout A, Flaherty A, Gerst S, Al-Ahmadie H, Ostrovnaya I, Bajorin DF. Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. Journal of Clinical Oncology. 29: 4606-4606. DOI: 10.1200/Jco.2011.29.15_Suppl.4606 |
0.345 |
|
| 2011 |
Balar AV, Milowsky MI, Apolo AB, Ostrovnaya I, Iasonos A, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Bajorin DF. Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC). Journal of Clinical Oncology. 29: 4566-4566. DOI: 10.1200/Jco.2011.29.15_Suppl.4566 |
0.318 |
|
| 2010 |
Ostrovnaya I, Nanjangud G, Olshen AB. A classification model for distinguishing copy number variants from cancer-related alterations. Bmc Bioinformatics. 11: 297. PMID 20525196 DOI: 10.1186/1471-2105-11-297 |
0.334 |
|
| 2010 |
Ostrovnaya I, Olshen AB, Seshan VE, Orlow I, Albertson DG, Begg CB. A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data. Statistics in Medicine. 29: 1608-21. PMID 20205270 DOI: 10.1002/Sim.3866 |
0.394 |
|
| 2010 |
Ostrovnaya I, Begg CB. Testing Clonal Relatedness of Tumors Using Array Comparative Genomic Hybridization: A Statistical Challenge Clinical Cancer Research. 16: 1358-1367. PMID 20179213 DOI: 10.1158/1078-0432.Ccr-09-2398 |
0.356 |
|
| 2010 |
Andrade V, Morrogh M, Giri D, Ostrovnaya I, Seshan V, Olvera N, Begg C, Morrow M, King T. Abstract P3-07-01: Clonal Relatedness between Lobular Carcinoma In Situ and Synchronous Malignant Lesions: Analysis of Fresh Frozen Tissue Using SNP Array Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-07-01 |
0.371 |
|
| 2009 |
Girard N, Ostrovnaya I, Lau C, Park B, Ladanyi M, Finley D, Deshpande C, Rusch V, Orlow I, Travis WD, Pao W, Begg CB. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5184-90. PMID 19671847 DOI: 10.1158/1078-0432.Ccr-09-0594 |
0.375 |
|
| 2009 |
Orlow I, Tommasi DV, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ, Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE, Begg CB. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. The Journal of Investigative Dermatology. 129: 1972-82. PMID 19282844 DOI: 10.1038/Jid.2009.4 |
0.378 |
|
| 2009 |
Fahy BN, D’Angelica M, DeMatteo RP, Blumgart LH, Weiser MR, Ostrovnaya I, Gonen M, Jarnagin WR. Synchronous Hepatic Metastases from Colon Cancer: Changing Treatment Strategies and Results of Surgical Intervention Annals of Surgical Oncology. 16: 361-370. PMID 19050976 DOI: 10.1245/S10434-008-0217-3 |
0.324 |
|
| 2008 |
Ostrovnaya I, Seshan VE, Begg CB. Comparison of properties of tests for assessing tumor clonality. Biometrics. 64: 1018-1022. PMID 18266893 DOI: 10.1111/J.1541-0420.2008.00988.X |
0.303 |
|
| 2007 |
Thompson EE, Pan L, Ostrovnaya I, Weiss LA, Gern JE, Lemanske RF, Nicolae DL, Ober C. Integrin beta 3 genotype influences asthma and allergy phenotypes in the first 6 years of life. The Journal of Allergy and Clinical Immunology. 119: 1423-9. PMID 17556058 DOI: 10.1016/J.Jaci.2007.03.029 |
0.474 |
|
| 2007 |
Bajorin DF, Ostrovnaya I, Iasonos A, Milowsky MI, Boyle M, Riches J. A nomogram predicting survival of patients (pts) with metastatic or unresectable urothelial cancer (UC) treated with cisplatin-based chemotherapy Journal of Clinical Oncology. 25: 5055-5055. DOI: 10.1200/Jco.2007.25.18_Suppl.5055 |
0.368 |
|
| 2005 |
Hoffjan S, Nicolae D, Ostrovnaya I, Roberg K, Evans M, Mirel DB, Steiner L, Walker K, Shult P, Gangnon RE, Gern JE, Martinez FD, Lemanske RF, Ober C. Gene-environment interaction effects on the development of immune responses in the 1st year of life. American Journal of Human Genetics. 76: 696-704. PMID 15726497 DOI: 10.1086/429418 |
0.485 |
|
| Show low-probability matches. |